On January 10, 2024, Ginkgo Bioworks Holdings, Inc., a leader in cell programming and biosecurity, announced preliminary unaudited financial highlights for the fiscal year ending December 31, 2023. The company expects to meet its 2023 guidance ranges for new programs and revenue, with total revenue anticipated between $250 and $260 million. Cell Engineering revenue is projected to be within the $145 to $150 million range, while Biosecurity revenue is expected to align with the guidance of up to $110 million. Ginkgo also reported strong growth in its biopharma customer base, including partnerships with Pfizer, Novo Nordisk, Merck, and Boehringer Ingelheim, potentially worth over $1.2 billion in aggregate payments and milestones. The company completed a pilot phase with Novo Nordisk and a gene therapy collaboration with Biogen. Additionally, Ginkgo's partnership with...Show More

On January 10, 2024, Ginkgo Bioworks Holdings, Inc., a leader in cell programming and biosecurity, announced preliminary unaudited financial highlights for the fiscal year ending December 31, 2023. The company expects to meet its 2023 guidance ranges for new programs and revenue, with total revenue anticipated between $250 and $260 million. Cell Engineering revenue is projected to be within the $145 to $150 million range, while Biosecurity revenue is expected to align with the guidance of up to $110 million. Ginkgo also reported strong growth in its biopharma customer base, including partnerships with Pfizer, Novo Nordisk, Merck, and Boehringer Ingelheim, potentially worth over $1.2 billion in aggregate payments and milestones. The company completed a pilot phase with Novo Nordisk and a gene therapy collaboration with Biogen. Additionally, Ginkgo's partnership with Google Cloud is set to train AI models using proprietary and public data, aiming to foster more pharmaceutical partnerships in 2024. Ginkgo concluded the year with nearly $950 million in cash and equivalents, providing a solid financial foundation for strategic initiatives and a move towards profitability. The full financial results for the fourth quarter and the entire year of 2023 will be reported in February 2024, at which time Ginkgo will also provide its outlook for 2024. The announcement was made in conjunction with Ginkgo's participation in the 42nd Annual J.P. Morgan Healthcare Conference.